WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001031010) PDGF-ASSOCIATED PROTEINS AND NUCLEIC ACIDS ENCODING THE SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/031010    International Application No.:    PCT/US2000/029391
Publication Date: 03.05.2001 International Filing Date: 25.10.2000
Chapter 2 Demand Filed:    22.05.2001    
IPC:
A61K 38/00 (2006.01), A61K 48/00 (2006.01), C07K 14/475 (2006.01)
Applicants: CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive 11th Floor New Haven, CT 06511 (US) (For All Designated States Except US).
BURGESS, Catherine [US/US]; (US) (For US Only).
RASTELLI, Luca [IT/US]; (US) (For US Only)
Inventors: BURGESS, Catherine; (US).
RASTELLI, Luca; (US)
Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C. One Financial Center Boston, MA 02111 (US)
Priority Data:
60/161,315 25.10.1999 US
09/695,366 24.10.2000 US
Title (EN) PDGF-ASSOCIATED PROTEINS AND NUCLEIC ACIDS ENCODING THE SAME
(FR) PROTEINES ASSOCIEES A PDGF ET ACIDES NUCLEIQUES CODANT CES PROTEINES
Abstract: front page image
(EN)The present invention provides novel isolated PRO polynucleotides and polypeptides encoded by the PRO polynucleotides. Also provided are the antibodies that immunospecifically bind to a PRO polypeptide or any derivative, variant, mutant or fragment of the PRO polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the PRO polypeptide, PRO polynucleotide, and PRO antibody are utilized in the detection and prophylactic and therapeutic treatment of a broad range of pathological states, as well as to various other uses.
(FR)L'invention concerne de nouveaux polynucléotides isolés PRO et des polypeptides codés par ces polynucléotides PRO. Elle concerne également les anticorps se fixant de façon immunospécifique à un polypeptide PRO ou à tout dérivé, toute variante, tout mutant ou fragment du polypeptide PRO, du polynucléotide ou de l'anticorps. Elle concerne, de plus, des procédés consistant à utiliser ce polypeptide PRO, ce polynucléotide PRO et cet anticorps PRO pour la détection et le traitement prophylactique et thérapeutique d'une variété importante d'états pathologiques, ainsi que pour différentes autres mises en application.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)